MOODY’S-ANALYTICS
9.11.2020 10:02:09 CET | Business Wire | Press release
Moody’s Analytics announced today a new partnership with The Business School (formerly Cass) at City, University of London, to build a database of loan-level commercial real estate (CRE) information covering the UK and Europe. The initiative will extend the Business School’s UK CRE lending survey under the Moody’s Analytics Data Alliance framework.
The COVID-19 pandemic has disrupted CRE fundamentals and highlighted the need for greater clarity around market drivers across sectors and between geographies. By participating in this initiative, lenders and other market participants will benefit from access to aggregate industry data, for enhanced market clarity, as well as robust analytics for benchmarking.
“The City-Moody’s Analytics initiative offers the exciting prospect of granular data pooling across the commercial real estate finance market. This will improve market transparency and allow for more robust data-driven analysis, thus strengthening informed credit flows,” said Peter Cosmetatos, CEO of the Commercial Real Estate Finance Council Europe. “Industry leaders and the Bank of England have previously recognized the importance of loan-level data pooling—this market-led initiative could be an important step towards achieving it.”
The data will be aggregated as part of the Moody’s Analytics Data Alliance, a collaborative effort of leading financial institutions and Moody's Analytics to create the world's largest collection of credit risk data. It is one of the world’s largest and most comprehensive data consortia with participation from more than 120 of the world’s leading banks, insurers, asset managers, and multi-lateral development banks. This initiative expands the Moody’s Analytics US CRE data consortium, which comprises data on loans worth $588B+, in 105,000+ properties covering 361 metropolitan areas, to the UK and Europe.
“We are delighted to partner with The Business School at City, University of London to create this essential CRE resource in the UK and Europe, which aligns with our commitment to helping the CRE industry address fundamental shifts caused by the pandemic,” said Jacob Grotta, Head of Risk and Finance Solutions at Moody’s Analytics. “The aim of the Data Alliance is to provide institutions with high-quality data, robust analytics, and advanced modelling capabilities for managing credit risk throughout the cycle.”
Co-leading the initiative is Dr. Nicole Lux, Senior Research Fellow at The Business School (formerly Cass), University of London. With extensive experience in real estate data collection, Dr. Lux conducts the UK CRE lending survey, which has been gathering data from more than 100 participant firms for more than 20 years to produce a comprehensive record of CRE lending in the market. Dr. Lux will work with industry participants to gather the loan-level information on behalf of the City-Moody’s Analytics initiative in the UK.
“Moody’s Analytics brings a wealth of expertise in collecting and parsing CRE and credit data in the US market,” said Dr. Lux. “I’m looking forward to working with the Data Alliance to broaden the scope of our CRE lending survey to encompass loan-level data and create more powerful analytics and benchmarking for CRE market participants in Europe.”
Learn more about the Moody’s Analytics Data Alliance.
About Moody’s Analytics
Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide, with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter and LinkedIn .
Moody's Analytics is a subsidiary of Moody's Corporation (NYSE: MCO). Moody's Analytics is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.8 billion in 2019, employs approximately 11,200 people worldwide and maintains a presence in 40 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005455/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 08:00:00 CEST | Press release
€50 million financing package from funds and accounts managed by BlackRock will support IQM to scale operations, accelerate product development, and strengthen its market position. The facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing as IQM prepares for public listing. IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom